Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait

• Published in: Hepatology international 2021-08, Vol.15 (4), p.912-921
• Main Authors: Sanai, Faisal M., Al Khathlan, Abdullah, Al Fadhli, Ahmad, Jazzar, Ahmad S., Hashim, Al Moutaz, Mansour, Eid, Abaalkhail, Faisal, Hasan, Fuad, Al Mudaiheem, Hajer, Al Quraishi, Huda, Bottomley, Juliana, Alswat, Khalid A., Al Ghamdi, Mohammed, Farghaly, Mohamed, Fathy, Motaz, Awad, Nancy, Mohamed, Omneya, Kozma, Sam, Al-Hamoudi, Waleed, Al-jedai, Ahmed
• Format: Article
• Language: English
• Subjects: Carcinoma, Hepatocellular - epidemiology; Cirrhosis; Colorectal Surgery; Cost of Illness; Costs; Diabetes mellitus; Fatty liver; Fibrosis; Health care; Health policy; Hepatocellular carcinoma; Hepatology; Humans; Kuwait - epidemiology; Liver; Liver cancer; Liver cirrhosis; Liver diseases; Liver Neoplasms - epidemiology; Liver transplantation; Markov chains; Medicine; Medicine & Public Health; Non-alcoholic Fatty Liver Disease - epidemiology; Obesity; Original; Original Article; Patients; Public health; Resource utilization; Saudi Arabia - epidemiology; Standard of care; Surgery; United Arab Emirates - epidemiology
• ISSN: 1936-0533; 1936-0541
• DOI: 10.1007/s12072-021-10182-x

Background and aims The Middle East (ME) has a high prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), driven by obesity and type-2 diabetes mellitus (T2DM). Studies in Saudi Arabia (KSA) and United Arab Emirates (UAE) predict an escalating impact of NAFLD/NASH, particularly advanced fibrosis due to NASH (AF-NASH), increasing cases of cirrhosis, liver cancer and death. The scale of this burden in other ME countries is unknown with no reports of NAFLD/NASH healthcare resource utilization (HCRU) or costs. We estimated the clinical and economic burden of NAFLD/NASH in KSA, UAE and Kuwait. Methods Markov models populated with country-specific obesity and T2DM prevalence data estimated numbers and progression of NAFLD/NASH patients from 2018 to 2030. Model inputs, assumptions and outputs were collected from literature, national statistics, and expert consensus. Results Over 13 years, the KSA model estimated cases increasing as follows: patients with fibrosis F0–3 doubled to 2.5 m, compensated and decompensated cirrhosis and hepatocellular carcinoma trebled to 212,000; liver failure or transplant patients increased four-fold to 4,086 and liver-related death escalated from  200,000. Similar trends occurred in UAE and Kuwait. Discounted lifetime costs of NASH standard-care increased totaling USD40.41 bn, 1.59 bn and 6.36 bn in KSA, UAE (Emiratis only) and Kuwait, respectively. NASH-related costs in 2019 comprised, respectively, 5.83%, 5.80% and 7.66% of national healthcare spending. Conclusions NASH, especially AF-NASH, should be considered a higher priority in ME Public Health policy. Our analyses should inform health policy makers to mitigate the enormity of this escalating regional burden.